Environment
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
StateNorth DakotaIntroduced
SB 2370: AN ACT to provide for a legislative management study regarding prescription drug transparency reporting under the federal drug discount program.
Sean Cleary
SB 2370 status: Introduced — Filed with Secretary Of State 05/02 (updated Jun 11, 2025).
Source
OpenStates
Confidence
Low
Analysis basis
OpenStates summary
01
What this bill does
Official summary alongside an AI-generated read on where it stands and why.
Overall Score
65OUT OF 100
Score:65/100 civic fit
Risk:Low Risk
Impact:Low Impact 20/100
Constitutionality90%
Bipartisan50%
Public opinion70%
Bill summary
What changes
The bill authorizes a legislative management study regarding the transparency of drug pricing under federal discount programs.
Who is affected
Pharmaceutical companies participating in government discount programs and the state legislature.
Requirements and enforcement
The bill requires an inquiry into the price reporting practices of drug manufacturers.
Costs and funding
Not stated, but assumes administrative costs for the state legislature to conduct the study.
When it takes effect
Not stated; the study would likely occur during the legislative interim.
Potential benefits
Potential increased transparency in how federal drug discount programs operate and increased legislative knowledge.
Risks and tradeoffs
The study may not lead to substantive changes; potential for industry pushback regarding disclosure.
What is still unknown
The specific scope of the study, the duration, and whether it will focus on specific drug categories or the program as a whole.
02
Impact analysis
✦ AI analysisModeled effects across six domains, estimated from bill text and comparable legislation.
Economy
Positive outlook
60%
Benefits
- Potential for identifying cost-saving opportunities in state programs
- Encourages greater transparency in drug manufacturer pricing
- Promotes fair competition by auditing federal discount program compliance
Risks
- Imposes administrative compliance burdens on drug companies
- Creates regulatory uncertainty during the study period
- Risk of diverting state legislative resources toward a potentially inconclusive study
Society
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
Technology Industry
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
Civic Accountability
Positive outlook
75%
Benefits
- Increases legislative oversight of healthcare pricing
- Facilitates formal public reporting on pharmaceutical practices
- Improves government transparency in healthcare-related federal programs
Risks
- Legislative studies often lack enforcement mechanisms for non-compliance
- Risk that study results may be influenced by lobbying interests
- Potential for delay in policy action due to lengthy study timelines
Public Health & Safety
Positive outlook
60%
Benefits
- Focuses on maintaining the integrity of pharmaceutical discount programs
- Identifies potential barriers to the affordability of medications
- Aims to protect the efficacy of government-backed drug access
Risks
- Does not provide immediate relief for patient prescription costs
- Risk that the study fails to produce actionable health safety recommendations
- Focus on pricing may overlook broader clinical safety issues
03
How trustworthy & consequential it is
Sourcing already shown above, this is what the analysis found worth flagging.
Source
OpenStates
Official bill text or data from OpenStates.
Confidence
Low
Information is limited or incomplete.
Analysis basis
OpenStates summary
Source used for this bill's analysis.
Source note
This is a study bill; passage does not result in immediate changes to drug prices or industry regulations.
Analysis scope
Source provided is a brief summary, lacking specific study criteria or timeline details.
04
Where it stands
Official record- IntroducedCurrent
- CommitteeUpcoming
- Chamber votesUpcoming
- Final agreementUpcoming
- GovernorUpcoming
- EnactedUpcoming
05
How it affects your district
✦ Personalized
Set your location
Add your district to see how this bill may affect your community and who to contact.
Your Representatives
Your representatives appear here once you add your location.
06
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.